Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Completed · Phase 1/Phase 2
Conditions studied: Refractory Diffuse Large B Cell Lymphoma
In brief
The primary objective of phase 1 is to evaluate the safety of KTE-C19 and atezolizumab combination regimens. The primary objective of phase 2 is to evaluate the efficacy of KTE-C19 and atezolizumab, as measured by complete response rate in participants with refractory diffuse large B-cell lymphoma (DLBCL). Participants who received an infusion of KTE-C19 will complete the remainder of the 15 year follow-up assessments in a separate long-term follow-up study, KT-US-982-5968 (NCT05041309).
Key facts
- Study ID
- NCT02926833
- Run by
- Kite, A Gilead Company
- People needed
- 37
- Starts
- 2016-09-29
- Expected to finish
- 2023-01-12
- Last updated by the study team
- 2024-03-06
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- City of Hope — Duarte, California, United States
- Stanford Cancer Center — Palo Alto, California, United States
- H Lee Moffitt Cancer Center — Tampa, Florida, United States
- Dana Farber Cancer Institute — Boston, Massachusetts, United States
- University of Texas MD Anderson Cancer Center — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.